Pharmaceuticals 2010, 3(1), 125-145; doi:10.3390/ph3010125
Review

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

Received: 8 November 2009; in revised form: 7 January 2010 / Accepted: 11 January 2010 / Published: 12 January 2010
(This article belongs to the Special Issue Anti-Obesity Drugs)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.
Keywords: obesity; drug treatment; orlistat; sibutramine; rimonabant; leptin; ghrelin
PDF Full-text Download PDF Full-Text [261 KB, uploaded 12 January 2010 11:00 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Isidro, M.L.; Cordido, F. Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. Pharmaceuticals 2010, 3, 125-145.

AMA Style

Isidro ML, Cordido F. Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. Pharmaceuticals. 2010; 3(1):125-145.

Chicago/Turabian Style

Isidro, Mª Luisa; Cordido, Fernando. 2010. "Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options." Pharmaceuticals 3, no. 1: 125-145.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert